The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicenter comparative study

Annals of Surgery

Volumn 254, Issue 5, 2011, Pages 684-693

  Messager, Mathieu ^a   Lefevre, Jérémie H ^b   Pichot Delahaye, Virginie ^c   Souadka, Amine ^d   Piessen, Guillaume ^a   Mariette, Christophe ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HYDROXYUREA; IRINOTECAN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; FEMALE; FOLLOW UP; GASTRIC SIGNET RING CELL ADENOCARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METASTASIS; PERIOPERATIVE CHEMOTHERAPY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNET RING CARCINOMA; SURVIVAL; TUMOR GROWTH; TUMOR LOCALIZATION;

CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 80255125997     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182352647     Document Type: Conference Paper

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64. (Pubitemid 29094960)
3. Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878-887.
4. Wu H, Rusiecki JA, Zhu K, et al. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945-1952.
5. Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14(suppl 2):ii31-ii36. (Pubitemid 36874136)
6. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
7. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-1820. (Pubitemid 350044801)
8. Rougier P, Mahjoubi M, Lasser P, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer. 1994;30A:1269-1275. (Pubitemid 24322060)
9. Takiuchi H, Hirata I, Kawabe S, et al. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep. 2000;7:841-846.
10. Smith BR, Stabile BE. Extreme aggressiveness and lethality of gastric adeno-carcinoma in the very young. Arch Surg. 2009;144:506-510.
11. Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89:1418-1424.
12. Li C, Kim S, Lai JF, et al. Advanced gastric carcinoma with signet ring cell histology. Oncology. 2007;72:64-68. (Pubitemid 350249131)
13. Thésaurus National de Cancérologie digestive. http://www.snfge.asso.fr/01-bibliotheque/0g-thesaurus-cancerologie/publication5/ sommaire-thesaurus. asp#1288. Accessed June 16, 2011.
14. Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology. 1991;181:426-432.
15. Dittler HJ, Siewert JR. Role of endoscopic ultrasonography in gastric carcinoma. Endoscopy. 1993;25:162-166. (Pubitemid 23107977)
16. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FN-CLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721.
17. Japaneese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study. 1st English ed., Tokyo: Kanahara Shuppan; 1995.
18. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11:127-139. (Pubitemid 11080134)
19. Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarci-noma: which therapeutic approach? Lancet Oncol. 2011;12:296-305.
20. Watanabe H, Jass JR, Sobin LH. Histological Typing of Oesophageal and Gastric and Gastric Tumors. WHO International Histological Classification of Tumors. 2nd ed. Berlin: Springer-Verlag; 1990.
21. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
22. Sobin LH, Wittekind C, eds. UICC TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002.
23. Dindo D, Demartines N, Clavien P. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213. (Pubitemid 38963009)
24. Farquhar CM, Marjoribanks J, Lethaby A, et al. High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev. 2007;33:325-337. (Pubitemid 46778206)
25. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroe-sophageal junction. N Engl J Med. 2001;345:725-730.
26. Macdonald JS, Benedetti J, Smalley S. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol. 2009; 24(15S):4515, ASCO Annual Meeting Proceedings.
27. Hamilton S, Aaltonen L. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000.
28. Jonckheere N, Van Seuningen I. The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit Rev Oncog. 2008;14:177-196.
29. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012-2018. (Pubitemid 351551110)
30. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-197. (Pubitemid 30189900)
31. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol. 2010; 28(18S):4007, ASCO Annual Meeting Proceedings.
32. Bang Y, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
33. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-1737.